This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic NSCLC. All patients are infused with their autologous TIL (LN-145) followed by IL-2 administration between 3-24 hours after every 8-12 hours for a total of 6 doses. Cohort 1 will consist of patients whose tumors did not express PD-L1 (tumor proportion score [TPS] < 1%) prior to their CPI treatment. Cohort 2 will consist of those who do express PD-L1. Cohort 3 will consist of patients whose tumors do not express PD-L1 (TPS < 1%) prior to their CPI treatment and who are unable to safely undergo a surgical harvest for TIL generation.  The primary outcome measured will be objective response rate.

(IOV-LUN-202 , IRB 2020-1030)

IRB 2020-1036
A Phase 1, Open Label, Crossover Study to Establish Bioequivalence Between the Proposed Soft Gel Talazoparib Capsule Formulation and the Current Talazoparib Commercial Formulation and to Estimate the Food Effect on Pharmacokinetics of the Proposed Talazoparib Soft Gel Capsule Formulation in Participants with Advanced Solid Tumors
IRB 2020-0616
Click Here to Download All Cancer Trials Open to Accrual
Questions?  Please call us at 513-584-7698, or email us!

Research Recruitment just got an Upgrade!!

The new High Enroll mobile app is now available to UC Cancer Center members and outside affiliates. The app has a new look and exciting new features to support the recruitment of patients into our research studies.

The UC Cancer Center continues to partner with High Enroll, LLC, to make recruitment easier and more enjoyable. We hope you will find the updated mobile application even more helpful. The new app will continue to provide all the information you need at your fingertips for discussing research with a patient. Some of the new features include: more content fields for each study; updates on studies via push notifications; the ability to save a study as a “favorite”; the ability to share a specific study with an interested colleague; and the ability to provide scheduled coordinator contact coverage 24/7.

The upgraded version of the mobile app is available for anyone at UC or beyond. It takes only seconds to get the new app. You can scan the QR code above, download it directly from the App Store, or wait for us to provide you a download link from the previous High Enroll app.

If you have any questions, please research out to your UC Cancer Center research team or High Enroll at 513.993.0330.

A new co-driver in breast cancer

UC researchers have discovered 'gene cooperation' in cancer growth and can target treatments to stop it. The team created an animal model with an overproduction of both genes, HER2 and MED1, in the mammary gland. This helped researchers discover the key role MED1 played in helping HER2 promote breast tumor growth, spread and treatment resistance.

The findings suggest that targeting MED1, alone and in combination with current therapies, could be an effective treatment strategy for nearly 90% of breast cancer patients in clinics and combat treatment resistance to two widely used breast cancer therapies.
Click Here to Visit the UC Newsroom
UC Health Office of Clinical Research
Email Us
Check out our YouTube chanel!
Questions?  Please call us at 513-584-7698, or email us!
Copyright © 2019, All rights reserved.

UC Cancer Center Clinical Trials Office
200 Albert Sabin Way
Suite 4002A, ML 0502
Cincinnati, OH 45267-0502
513-584-7698    F 513-558-0071

Unsubscribe to this newsletter by emailing:

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
UCCI Clinical Trials · 200 Albert Sabin Way Ste 4002A · Ml 0502 · Cincinnati, OH 45267-0502 · USA